ReportWire

Tag: COVID

  • NCAA hands former Michigan coach Jim Harbaugh a 4-year show cause order for recruiting violations

    NCAA hands former Michigan coach Jim Harbaugh a 4-year show cause order for recruiting violations

    NCAA hands former Michigan coach Jim Harbaugh a 4-year show cause order for recruiting violations

    Uh, Sharon, uh, is the right man for the job. Uh, nobody else, uh, would be, I mean, that’s, that’s the guy and they got it right. And, uh, and things are, uh, see, they, we’re top rated, uh, team right now, top five team and I, I still think of it as one, you know, the Chargers and the Michigan Wolverines like one team. Um, so, um, in, in ***, in *** great place in *** great place that, um, much like when players, you know, leave the university to go on to the, uh, to the pros, you know, there’s ***, there’s *** passing of the baton that takes place, uh, and you see JJ Lee, but then I see, uh, Jaden Denel, uh, Alex Orgy, I mean, next day they’re, they’re on that, that field they’re thrown with, with receivers, uh, and, um, there’s an excitement there, I’ve been involved in that as *** player when, when the quarterback ahead of me, uh, uh, left or graduated and it’s the same for, for coaches, I mean, I’ve been talking to Sharon, he’s on, I mean, the guy is on, on fire right now. I mean, he’s, uh, he’s, uh, he’s working, um, recruiting and, um, coaches like Jesse Minter. I mean, he’s ***, he’s *** tremendous coach. Um, we’re going through *** process right now. Um, Ben Herbert, I can’t confirm that he’s gonna be gonna be *** charger and, uh, I love the, the passing of the baton was there, uh, to, uh, to Justin Tress. J Tress, you know, uh, hugged it out and right there in the, right there in the blue M right in the middle of the, uh, the, of the weight room. So, uh, in great hands and, um, yeah, always gonna, always gonna be *** loyal Wolverine.

    NCAA hands former Michigan coach Jim Harbaugh a 4-year show cause order for recruiting violations

    The NCAA announced a four-year show-cause order for former Michigan coach Jim Harbaugh on Wednesday for impermissible contact with recruits and players while access was restricted during the COVID-19 pandemic.The NCAA said Harbaugh, who left his alma mater to coach the Los Angeles Chargers after last season’s national championship, “engaged in unethical conduct, failed to promote an atmosphere of compliance and violated head coach responsibility obligations.”The NCAA had already put Michigan on three years of probation along with a fine and recruiting limits after reaching a negotiated resolution that was approved by the committee on infractions in the same matter.Harbaugh did not go along with the agreement, disputing allegations he failed to to cooperate with investigators. Harbaugh’s attorney, Tom Mars, has said the coach was not invited to participate in the settlement process or aware that an agreement had been reached between the school on the NCAA. “The panel noted that Harbaugh’s intentional disregard for NCAA legislation and unethical conduct amplified the severity of the case and prompted the panel to classify Harbaugh’s case as Level I-Aggravated, with penalties to include a four-year show-cause order. Subsumed in the show-cause order is a one-season suspension for Harbaugh,” the NCAA said.The show-cause order covers 2024-28 and would require a school wanting to hire Harbaugh to suspend him for the first full season. After that, Harbaugh would be barred from athletics-related activities, including team travel, practice, video study, recruiting and team meetings until the order expires.The recruiting case is separate from the NCAA’s investigation into impermissible in-person scouting and sign stealing that roiled Michigan’s national championship season in 2023, and resulted in a three-game suspension of Harbaugh by the Big Ten. The multiple cases could open up Michigan to being deemed a repeat violator by the NCAA, which could trigger harsher sanctions. The fine was not announced, though NCAA guidelines call for a fine of $5,000 for mitigated Level I violations.The NCAA, which also said Harbaugh is suspended for one season as part of its penalties, is barred from working at any NCAA school in an athletic-related capacity.

    The NCAA announced a four-year show-cause order for former Michigan coach Jim Harbaugh on Wednesday for impermissible contact with recruits and players while access was restricted during the COVID-19 pandemic.

    The NCAA said Harbaugh, who left his alma mater to coach the Los Angeles Chargers after last season’s national championship, “engaged in unethical conduct, failed to promote an atmosphere of compliance and violated head coach responsibility obligations.”

    The NCAA had already put Michigan on three years of probation along with a fine and recruiting limits after reaching a negotiated resolution that was approved by the committee on infractions in the same matter.

    Harbaugh did not go along with the agreement, disputing allegations he failed to to cooperate with investigators. Harbaugh’s attorney, Tom Mars, has said the coach was not invited to participate in the settlement process or aware that an agreement had been reached between the school on the NCAA.

    “The panel noted that Harbaugh’s intentional disregard for NCAA legislation and unethical conduct amplified the severity of the case and prompted the panel to classify Harbaugh’s case as Level I-Aggravated, with penalties to include a four-year show-cause order. Subsumed in the show-cause order is a one-season suspension for Harbaugh,” the NCAA said.

    The show-cause order covers 2024-28 and would require a school wanting to hire Harbaugh to suspend him for the first full season. After that, Harbaugh would be barred from athletics-related activities, including team travel, practice, video study, recruiting and team meetings until the order expires.

    The recruiting case is separate from the NCAA’s investigation into impermissible in-person scouting and sign stealing that roiled Michigan’s national championship season in 2023, and resulted in a three-game suspension of Harbaugh by the Big Ten.

    The multiple cases could open up Michigan to being deemed a repeat violator by the NCAA, which could trigger harsher sanctions. The fine was not announced, though NCAA guidelines call for a fine of $5,000 for mitigated Level I violations.

    The NCAA, which also said Harbaugh is suspended for one season as part of its penalties, is barred from working at any NCAA school in an athletic-related capacity.

    Source link

  • COVID is rising in California. Here’s how to protect yourself from FLiRT subvariants

    COVID is rising in California. Here’s how to protect yourself from FLiRT subvariants

    There are growing signs of an uptick in COVID-19 in California thanks to the new FLiRT subvariants.

    It’s far too early to know if FLiRT will be a major change in the COVID picture, and so far the impacts have been small.

    But health officials are taking note and are urging Californians — especially those at risk — to be prepared.

    Here’s rundown of what we know and how you can protect yourself.

    What are FLiRT subvariants?

    The FLiRT subvariants — officially known as KP.2, KP.3 and KP.1.1 — have overtaken the dominant winter variant, JN.1. For the two-week period that ended Saturday, they were estimated to account for a combined 50.4% of the nation’s coronavirus infections, up from 20% a month earlier.

    Despite their increased transmissibility, the new mutations don’t appear to result in more severe disease. And the vaccine is expected to continue working well, given the new subvariants are only slightly different from the winter version.

    “It’s been quite a while since we’ve had a new dominant variant in the U.S.,” Dr. David Bronstein, an infectious diseases specialist at Kaiser Permanente Southern California told The Times earlier this month. “With each of these variants that takes over from the one before it, we do see increased transmissibility — it’s easier to spread from person to person. So, that’s really the concern with FLiRT.”

    What are officials seeing?

    Doctors say they are not seeing a dramatic jump in severely ill people, and COVID levels still remain relatively low. But there are signs of a rise in infections that could lead to the summer coronavirus season beginning earlier than expected.

    “COVID-19 concentrations in wastewater have suggested increases in several regions across California since early May. Test positivity for COVID-19 has been slowly increasing since May,” the state Department of Public Health said in a statement to The Times on Friday.

    Over the seven-day period that ended Monday, about 3.8% of COVID-19 tests in California came back positive; in late April, that share was 1.9%. (Last summer’s peak test-positive rate was 12.8%, at the end of August.)

    In San Francisco, infectious disease doctors are noticing more people in the hospital with COVID-caused pneumonia.

    The Los Angeles County Department of Public Health has also started to see a very small uptick in cases in recent days. And Kaiser Permanente Southern California is reporting a small increase in outpatient COVID-19 cases.

    How can I protect myself?

    Vaccines

    Doctors urged people to consider getting up to date on their vaccinations — particularly if they are at higher risk of severe complications from COVID-19.

    In California, just 36% of seniors ages 65 and older have received the updated COVID-19 vaccine that first became available in September. The U.S. Centers for Disease Control and Prevention has urged everyone ages 6 months and older to get one dose of the updated vaccine. A second dose is also recommended for those ages 65 and older, as long as at least four months have passed since their last shot.

    It’s especially important that older people get at least one updated dose. Of the patients he has seen recently who had serious COVID, said UC San Francisco infectious diseases specialist Dr. Peter Chin-Hong, all of them hadn’t gotten an updated vaccine since September, and were older or immunocompromised.

    Behavior

    Avoid sick people. Some sick people might pass off their symptoms as a “cold,” when it could be the start of a COVID-19 illness.

    Testing

    Test if you’re sick, and test daily. It’s sometimes taking longer after the onset of illness for a COVID-19 rapid test to show up as positive. Consider taking a rapid COVID test once a day for three to five consecutive days after the onset of cough-and-cold symptoms, said Dr. Elizabeth Hudson, regional chief of infectious disease at Kaiser Permanente Southern California. Doing so can help the sickened person take measures to later isolate themselves and limit spread of the illness to others.

    Planning

    Have a plan to ask for Paxlovid if you become ill. Paxlovid is an antiviral drug that, when taken by people at risk for severe COVID-19 who have mild-to-moderate illness, reduces the risk of hospitalization and death.

    Masks are much less common these days but can still be a handy tool to prevent infection. Wearing a mask on a crowded flight where there are coughing people nearby can help reduce the risk of infection.

    How can I protect my family and friends?

    The U.S. Centers for Disease Control and Prevention has recently eased COVID isolation guidance, given that the health impacts of COVID-19 are lower than they once were, due to the availability of vaccines, anti-COVID medicines such as Paxlovid and increased population immunity.

    There are fewer people getting hospitalized and dying, and fewer reports of complications such as multi-inflammatory syndrome in children.

    Still, doctors say it remains prudent to take common sense steps to avoid illness and spreading the disease to others, given that COVID still causes significant health burdens that remain worse than the flu. Nationally, since the start of October, more than 43,000 people have died of COVID; by contrast, flu has resulted in an estimated 25,000 fatalities over the same time period.

    While the prevalence of long COVID has been going down, long COVID can still be a risk any time someone gets COVID.

    Here’s a guide on what to do if you get COVID-19:

    Stay home and away from others while sick, plus a day after you’ve recovered

    The CDC says people should stay home and away from others in their household until at least 24 hours after their respiratory viral symptoms are getting better overall, and they have not had a fever (and are not using fever-reducing medicine). Previously, the CDC suggested people with COVID isolate for at least five days, and take additional precautions for a few more days.

    In terms of deciding when symptoms are getting better overall, what’s most important is “the overall sense of feeling better and the ability to resume activities,” the CDC says. A lingering cough by itself can last beyond when someone is contagious, the CDC said.

    The Los Angeles County Department of Public Health also recommends testing yourself using a rapid test, and getting a negative result, before leaving isolation.

    The agency also suggests staying away from the elderly and immunocompromised people for 10 days after you start to feel sick.

    Take additional precautions after you recover in case you’re still contagious

    People who have recovered from COVID-19 may still be contagious a few days after they have recovered. The CDC suggests taking added precautions for five days after they leave their household and resume spending time with others to keep others safe. They include:

    • Wearing a well-fitting mask;
    • Continuing to test for COVID-19. If positive, it’s likely you’re more likely to infect others, still;
    • Keeping distance from other people;
    • Increasing air circulation by opening windows, turning on air purifiers, gathering outdoors if meeting with people;
    • And sticking with enhanced hygiene: washing and sanitizing hands often, cleaning high-touch surfaces, and covering coughs and sneezes.

    Masking for 10 days to protect others

    The L.A. County Department of Public Health says people with COVID-19 need to wear a well-fitting mask for 10 days after starting to feel sick, even if signs of illness are improving, to reduce the chance that other people could get infected. Masks can be removed sooner if you have two consecutive negative test results at least one day apart, the agency says.

    Be aware of COVID rebound

    COVID rebound can occur when people with COVID-19 feel better, but then start to feel sick two to eight days after they’ve recovered. Some people may also test positive again. COVID rebound can result in you becoming infectious again, capable of infecting those with whom you interact.

    Rebound can happen whether or not you take Paxlovid.

    Officials say if you feel sick again after having recovered from COVID, go back to following the same instructions to stay at home and away from other people during the first phase of the illness.

    If you test positive but have no symptoms

    The CDC says if you never had any symptoms, but test positive, take additional precautions for the next five days, such as masking up, testing, increasing air circulation, keeping distance and washing hands often.

    The L.A. County Department of Public Health recommends wearing a well-fitting mask for 10 days after testing positive for COVID-19, and also avoiding contact with any high-risk people for 10 days after starting to feel sick, such as the elderly and immunocompromised people. You can remove your mask sooner if you have two consecutive negative tests at least one day apart.

    L.A. County health officials recommend close contacts of people who have COVID-19 wear a well-fitting mask around other people for 10 days after their last exposure. They suggest getting tested three to five days after their last exposure.

    Rong-Gong Lin II

    Source link

  • Razer hit with $1.1M FTC fine over glowing ‘N95’ mask COVID claims | TechCrunch

    Razer hit with $1.1M FTC fine over glowing ‘N95’ mask COVID claims | TechCrunch

    The Federal Trade Commission hit Razer with a $1.1 million fine Tuesday. The order claims that the gaming accessory maker misled consumers by claiming that its flashy Zephyr mask was certified as N95-grade.

    “These businesses falsely claimed, in the midst of a global pandemic, that their face mask was the equivalent of an N95 certified respirator,” FTC Bureau of Consumer Projection Director Samuel Levine noted in a statement. “The FTC will continue to hold accountable businesses that use false and unsubstantiated claims to target consumers who are making decisions about their health and safety.”

    Razer has predictably pushed back against the commission’s claims.

    “We disagree with the FTC’s allegations and did not admit to any wrongdoing as part of the settlement,” a representative from the company said in a statement to TechCrunch. “It was never our intention to mislead anyone, and we chose to settle this matter to avoid the distraction and disruption of litigation and continue our focus on creating great products for gamers. Razer cares deeply about our community and is always looking to deliver technology in new and relevant ways.”

    The company went on to suggest that the complaint was cherrypicked, adding that it went out of its way to refund customers and end sales of the Zephyr.

    “The Razer Zephyr was conceived to offer a different and innovative face covering option for the community,” it notes. “The FTC’s claims against Razer concerned limited portions of some of the statements relating to the Zephyr. More than two years ago, Razer proactively notified customers that the Zephyr was not a N95 mask, stopped sales, and refunded customers.”

    The FTC is also officially barring sales of the mask and “making COVID-related health misrepresentations or unsubstantiated health claims about protective health equipment.” It goes a step further, “prohibit[ing] the defendants from representing the health benefits, performance, efficacy, safety, or side effects of protective goods and services (as defined in the proposed order), unless they have competent and reliable scientific evidence to support the claims made.”

    The filing suggests that Razer intentionally deceived consumers into believing that the $100 mask would protect against COVID. Certainly the virus was very much top of mind when the product first dropped in October 2021.

    The order is currently awaiting approval and signature from a District Court judge.

    Brian Heater

    Source link

  • What Kate Garraway has said about grieving for husband Derek amid ‘concern from friends’

    What Kate Garraway has said about grieving for husband Derek amid ‘concern from friends’

    Kate Garraway lost her husband Derek Draper in January, following his long battle with Covid and its after-effects.

    Tonight (March 26), Kate returns to our screens with a new documentary, Kate Garraway: Derek’s Story.

    However, friends of the TV star are reportedly concerned for Kate’s unrelenting work ethic as she navigates grieving her partner. Read on for everything Kate has said about grieving her beloved husband Derek.

    Kate lost her husband Derek in January (Credit: ITV)

    Kate Garraway on grieving her husband Derek Draper

    A source recently told Bella Magazine about Kate’s friends’ concern. They claimed: “Kate has sworn that juggling both Good Morning Britain and her radio show has been a lifeline, offering a glimmer of hope and distraction as she continues to deal with the unimaginable grief of losing your partner.

    Some of her friends are concerned that she needs to take a break.

    “However, some of her friends are concerned that she needs to take a break.”

    Kate initially announced Derek’s death on Instagram, in a heartwrenching tribute. She said: “I’m sad to have to tell you all that my darling husband Derek has passed away.

    “As some of you may know he has been critically ill following a cardiac arrest in early December which, because of the damage inflicted by Covid in March 2020, led to further complications.

    “Derek was surrounded by his family in his final days and I was by his side holding his hand throughout the last long hours and when he passed.

    “I have so much more to say, and of course I will do so in due course, but for now I just want to thank all the medical teams who fought so hard to save him and to make his final moments as comfortable and dignified as possible.

    “Sending so much love and thanks to all of you who have so generously given our family so much support. Rest gently and peacefully now Derek, my love, I was so lucky to have you in my life.”

    Kate Garraway sends message to GMB viewers after death of husband Derek

    Kate shared a heartfelt message with GMB viewers shortly after the loss of Derek, which Susanna Reid relayed on her behalf. She said that grief was “isolating”.

    The host thanked her fans for their support, stating: “They are an extraordinary comfort and I am so lucky to feel connected to you all through these messages at this time when the raw pain of grief can be so isolating.”

    She went on to gush: “I am certain that it is the support that you have given me and sent to Derek that has sustained us through these tough nearly four years, motivating us to fight on for each other, and for those that can’t fight for themselves, and it will sustain us to continue that fight in the weeks and months and years to come.

    “I look forward to waking up with you very soon again on Good Morning Britain to celebrate life in all its wonder and challenge again.”

    Kate on being in ‘bubble of grief’

    Ben Shephard appeared on GMB just days after Derek’s death and as a close friend of Kate, relayed his most recent discussion with her, where Kate touched on suffering through grief.

    He explained: “It is the first time I have been on since sadly we heard of Derek’s passing last Friday. I just thought it would be alright to, firstly, on Kate’s behalf, I spoke to Kate last night.

    “She again reiterated what she said on Monday which is a huge, huge thank you to everybody who sent her and her family a message.”

    She said she is sort of in a strange bubble of her own numbness of grief at the moment.

    Ben continued: “She said she is sort of in a strange bubble of her own numbness of grief at the moment. Her, Billy, and Darcey are hunkering down together.”

    The presenter went on: “They are in the next stages of working out what happens. There’s a lot of admin to do when you lose someone. In that brilliant way yesterday, she said: ‘I have to go out to go and register the death.’”

    Ben Shephard presenting Good Morning Britain alongside Kate Garraway
    Ben Shephard spoke about Kate Garraway’s grief (Credit: YouTube)

    Kate Garraway on caring for husband Derek

    Just days after laying Derek Draper to rest, Kate opened up about her struggles as a carer for her husband.

    Chatting on GMB, she said: “I think for people watching, they will know two things that are in a caring position – how unbelievably hard it is but what an honour it is too.

    “And how much I wish I was caring today because it’s you know, it’s an incredible thing to be that line of defence against the world and what happens to us all in life.

    I know I didn’t get it all right and I have lots of regrets of things I should have done more of.

    “To be able to be that person there for somebody, it’s the ultimate honour and privilege, isn’t it? I know I didn’t get it all right and I have lots of regrets of things I should have done more of and wished I had spent less time fretting about.

    “But it is a huge honour and what you do will be something that builds your life forever, it’s a gift but also you get so much for it as well.”

    Kate Garraway on GMB
    Kate Garraway’s husband Derek Draper died in January (Credit: ITV)

    Derek Draper funeral

    In an interview last week, ahead of the airing of Kate’s new documentary about husband Derek, Kate opened up about how she felt after the funeral.

    Speaking to The Sunday Times, Kate said: “I knew that what was said in the church would stay in the church, and wasn’t going to be broadcast or written up. I just trusted people not to do that.

    “But the day felt like an out-of-body experience, like it wasn’t quite real. I got home from the funeral and thought, ‘I can’t wait to tell Derek about this’. And that’s the maddest thing.”

    She added: “Of course I am glad he is at peace, but he never said, ‘I can’t do this any more.’ He always said, ‘How am I going to get better?’ So I knew that he would fundamentally be sad to have lost the fight. I’m just trying to take things really slowly, and sleep.”

    Derek Draper death

    Derek Draper died in January following a near four-year battle with the effects of Covid-19.

    Kate’s documentary, Kate Garraway: Derek’s Story, will be the third documentary about Derek, following on from Finding Derek and Caring for Derek.

    Read more: Kate Garraway admits husband Derek Draper felt like a ‘total failure and burden’ before his death in emotional GMB interview

    JOIN ED!’s ANT AND DEC NEWS CHANNEL ON WHATSAPP – IN THESE 4 SIMPLE STEPS USING THE INVITE LINK HERE

    How to join Ant and Dec news WhatsApp channel

    Kate Garraway: Derek’s Story airs Tuesday 26th March at 9pm on ITV1, ITVX and STV.

    Want to share a message with Kate? Leave them on our Facebook page @EntertainmentDailyFix.

    Emily Towers

    Source link

  • Why Are We Still Flu-ifying COVID?

    Why Are We Still Flu-ifying COVID?

    Four years after what was once the “novel coronavirus” was declared a pandemic, COVID remains the most dangerous infectious respiratory illness regularly circulating in the U.S. But a glance at the United States’ most prominent COVID policies can give the impression that the disease is just another seasonal flu. COVID vaccines are now reformulated annually, and recommended in the autumn for everyone over the age of six months, just like flu shots; tests and treatments for the disease are steadily being commercialized, like our armamentarium against flu. And the CDC is reportedly considering more flu-esque isolation guidance for COVID: Stay home ’til you’re feeling better and are, for at least a day, fever-free without meds.

    These changes are a stark departure from the earliest days of the crisis, when public-health experts excoriated public figures—among them, former President Donald Trump—for evoking flu to minimize COVID deaths and dismiss mitigation strategies. COVID might still carry a bigger burden than flu, but COVID policies are getting more flu-ified.

    In some ways, as the population’s immunity has increased, COVID has become more flu-like, says Roby Bhattacharyya, a microbiologist and an infectious-disease physician at Massachusetts General Hospital. Every winter seems to bring a COVID peak, but the virus is now much less likely to hospitalize or kill us, and somewhat less likely to cause long-term illness. People develop symptoms sooner after infection, and, especially if they’re vaccinated, are less likely to be as sick for as long. COVID patients are no longer overwhelming hospitals; those who do develop severe COVID tend to be those made more vulnerable by age or other health issues.

    Even so, COVID and the flu are nowhere near the same. SARS-CoV-2 still spikes in non-winter seasons and simmers throughout the rest of the year. In 2023, COVID hospitalized more than 900,000 Americans and killed 75,000; the worst flu season of the past decade hospitalized 200,000 fewer people and resulted in 23,000 fewer deaths. A recent CDC survey reported that more than 5 percent of American adults are currently experiencing long COVID, which cannot be fully prevented by vaccination or treatment, and for which there is no cure. Plus, scientists simply understand much less about the coronavirus than flu viruses. Its patterns of spread, its evolution, and the durability of our immunity against it all may continue to change.

    And yet, the CDC and White House continue to fold COVID in with other long-standing seasonal respiratory infections. When the nation’s authorities start to match the precautions taken against COVID with those for flu, RSV, or common colds, it implies “that the risks are the same,” Saskia Popescu, an epidemiologist at the University of Maryland, told me. Some of those decisions are “not completely unreasonable,” says Costi Sifri, the director of hospital epidemiology at UVA Health, especially on a case-by-case basis. But taken together, they show how bent America has been on treating COVID as a run-of-the-mill disease—making it impossible to manage the illness whose devastation has defined the 2020s.

    Each “not completely unreasonable” decision has trade-offs. Piggybacking COVID vaccines onto flu shots, for instance, is convenient: Although COVID-vaccination rates still lag those of flu, they might be even lower if no one could predict when shots might show up. But such convenience may come at the cost of protecting Americans against COVID’s year-round threat. Michael Osterholm, an epidemiologist at the University of Minnesota School of Public Health, told me that a once-a-year vaccine policy is “dead wrong … There is no damn evidence this is a seasonal virus yet.” Safeguards against infection and milder illness start to fade within months, leaving people who dose up in autumn potentially more susceptible to exposures by spring. That said, experts are still torn on the benefits of administering the same vaccine more than once a year—especially to a public that’s largely unwilling to get it. Throughout the pandemic, immunocompromised people have been able to get extra shots. And today, an advisory committee to the CDC voted to recommend that older adults once again get an additional dose of the most recently updated COVID vaccine in the coming months. Neither is a pattern that flu vaccines follow.

    Dropping the current COVID-isolation guideline—which has, since the end of 2021, recommended that people cloister for five days—may likewise be dangerous. Many Americans have long abandoned this isolation timeline, but given how new COVID is to both humanity and science, symptoms alone don’t yet seem enough to determine when mingling is safe, Popescu said. (The dangers are even tougher to gauge for infected people who never develop fevers or other symptoms at all.) Researchers don’t currently have a clear picture of how long people can transmit the virus once they get sick, Sifri told me. For most respiratory illnesses, fevers show up relatively early in infection, which is generally when people pose the most transmission risk, says Aubree Gordon, an epidemiologist at the University of Michigan. But although SARS-CoV-2 adheres to this same rough timeline, infected people can shed the virus after their symptoms begin to resolve and are “definitely shedding longer than what you would usually see for flu,” Gordon told me. (Asked about the specifics and precise timing of the update, a CDC spokesperson told me that there were “no updates to COVID guidelines to announce at this time,” and did not respond to questions about how flu precedents had influenced new recommendations.)

    At the very least, Emily Landon, an infectious-disease physician at the University of Chicago, told me, recommendations for all respiratory illnesses should tell freshly de-isolated people to mask for several days when they’re around others indoors; she would support some change to isolation recommendations with this caveat. But if the CDC aligns the policy fully with its flu policy, it might not mention masking at all.

    Several experts told me symptom-based isolation might also remove remaining incentives to test for the coronavirus: There’s little point if the guidelines for all respiratory illnesses are essentially the same. To be fair, Americans have already been testing less frequently—in some cases, to avoid COVID-specific requirements to stay away from work or school. And Osterholm and Gordon told me that, at this point in the pandemic, they agree that keeping people at home for five days isn’t sustainable—especially without paid sick leave, and particularly not for health-care workers, who are in short supply during the height of respiratory-virus season.

    But the less people test, the less they’ll be diagnosed—and the less they’ll benefit from antivirals such as Paxlovid, which work best when administered early. Sifri worries that this pattern could yield another parallel to flu, for which many providers hesitate to prescribe Tamiflu, debating its effectiveness. Paxlovid use is already shaky; both antivirals may end up chronically underutilized.

    Flu-ification also threatens to further stigmatize long COVID. Other respiratory infections, including flu, have been documented triggering long-term illness, but potentially at lower rates, and to different degrees than SARS-CoV-2 currently does. Folding this new virus in with the rest could make long COVID seem all the more negligible. What’s more, fewer tests and fewer COVID diagnoses could make it much harder to connect any chronic symptoms to this coronavirus, keeping patients out of long-COVID clinics—or reinforcing a false portrait of the condition’s rarity.

    The U.S. does continue to treat COVID differently from flu in a few ways. Certain COVID products remain more available; some precautions in health-care settings remain stricter. But these differences, too, will likely continue to fade, even as COVID’s burden persists. Tests, vaccines, and treatments are slowly commercializing; as demand for them drops, supply may too. And several experts told me that they wouldn’t be surprised if hospitals, too, soon flu-ify their COVID policies even more, for instance by allowing recently infected employees to return to work once they’re fever-free.

    Early in the pandemic, public-health experts hoped that COVID’s tragedies would prompt a rethinking of all respiratory illnesses. The pandemic showed what mitigations could do: During the first year of the crisis, isolation, masking, distancing, and shutdowns brought flu transmission to a near halt, and may have driven an entire lineage of the virus to extinction—something “that never, in my wildest dreams, did I ever think would be possible,” Landon told me.

    Most of those measures weren’t sustainable. But America’s leaders blew right past a middle ground. The U.S. could have built and maintained systems in which everyone had free access to treatments, tests, and vaccines for a longer list of pathogens; it might have invested in widespread ventilation improvements, or enacted universal sick leave. American homes might have been stocked with tests for a multitude of infectious microbes, and masks to wear when people started to cough. Vaccine requirements in health-care settings and schools might have expanded. Instead, “we seem to be in a more 2019-like place than a future where we’re preventing giving each other colds as much as we could,” Bhattacharyya told me.

    That means a return to a world in which tens of thousands of Americans die each year of flu and RSV, as they did in the 2010s. With COVID here to stay, every winter for the foreseeable future will layer on yet another respiratory virus—and a particularly deadly, disabling, and transmissible one at that. The math is simple: “The risk has overall increased for everyone,” Landon said. That straightforward addition could have inspired us to expand our capacity for preserving health and life. Instead, our tolerance for suffering seems to be the only thing that’s grown.

    Katherine J. Wu

    Source link

  • Fact check: Are COVID vaccine recipients ineligible to donate blood in NC?

    Fact check: Are COVID vaccine recipients ineligible to donate blood in NC?

    If you have received a COVID vaccine, you are eligible to give blood – but you may have to wait before donating.

    If you have received a COVID vaccine, you are eligible to give blood – but you may have to wait before donating.

    An ongoing national blood shortage could delay critical medical procedures, Dr. Nick Bandarenko, Duke Health’s medical director of transfusion services, told ABC11 last month.

    “Surgery, transplant or accident in a car. Suddenly there’s a need for blood,” said Dr. Bandarenko. “The Red Cross is one of the major suppliers in our region. They’ve asked us to exercise conservation measures to make sure those who truly need blood will have it available.”

    But despite the critical need for blood donors, there’s been some debate online about whether those who have received a COVID vaccine are eligible to donate.

    “The American Red Cross is now asking blood donors if they ever received the Covid vaccine,” an X user posted last week. “If you answer Yes, they want you to call ahead to see if you’re still eligible. I thought the vax was ‘safe and effective’? What info are they hiding from us?”

    Similar rumors have been spread on Facebook and TikTok, Snopes reported — but the claims concerning ineligibility are false.

    If you have received a COVID vaccine, you are eligible to give blood — but in rare cases you may have to wait before donating.

    Do I have to wait to give blood after getting vaccinated?

    In most cases, there is no wait time to donate blood for those who received the COVID vaccine, according to the American Red Cross.

    The Red Cross says those who received vaccines from the following manufacturers and are symptom-free do not have to wait to give blood:

    However, if you got a vaccine from a manufacturer not listed above, or you don’t know what type of vaccine you received, you’ll have to wait two weeks before donating blood, according to the Red Cross.

    How do I know which type of vaccine I received?

    If you were vaccinated, you should have received a card or printout indicating which COVID vaccine you got, the Red Cross says.

    The Red Cross encourages donors to bring those cards with them to their appointments.

    Am I eligible to donate blood in NC?

    In North Carolina, you must be at least 16 years old and weigh at least 110 pounds to donate blood, according to UNC Medical Center. Donors under 18 must have a signed parental consent form to donate blood on the day of donation.

    “Donors should feel well and healthy on the day of donation and free of infectious diseases, including colds,” UNC Medical Center says.

    Additional eligibility criteria may apply to individuals with certain medical conditions, or who are on medication, according to the Red Cross.

    Related stories from Charlotte Observer

    Evan Moore is a service journalism reporter for the Charlotte Observer. He grew up in Denver, North Carolina, where he previously worked as a reporter for the Denver Citizen, and is a UNC Charlotte graduate.

    Source link

  • Study Shows Faith, Spirituality Boost Mental Health, Especially During Isolation and Despair

    Study Shows Faith, Spirituality Boost Mental Health, Especially During Isolation and Despair

    Press Release


    Jan 10, 2024

    Post-COVID, spirituality helped people be resilient

    A study released this week shows the positive effects of spiritual and religious engagement during COVID and similar times of challenge. The Fetzer Institute-funded study “What Does Spirituality Mean to Us? A Study of Spirituality in the United States Since COVID” sought to uncover shifts in the nation’s understanding of faith and spirituality in the aftermath of the COVID-19 pandemic. The study was a two-year follow-up to Fetzer’s groundbreaking 2020 study of spirituality.

    “The data produced through this project is like the Webb telescope, only instead of distant stars, it has revealed the interior lives of many Americans — how they think and feel about their relationship to a higher power,” writes University of Notre Dame Professor David Campbell in the study’s introduction. “These innovative data show that spirituality is like a vaccine, inoculating people against isolation and despair.”

    The full study can be found here: https://fetzer.org/work/study-spirituality-america

    In a world where uncertainty often reigns, understanding the role of spirituality and faith becomes crucial. The Fetzer Institute’s recent study, conducted by the National Opinion Research Center (NORC) at the University of Chicago — a respected independent research institution — reveals key findings about America’s spiritual life amid the challenges of the COVID era.

    Key Insights show:
    —How spiritual and religious practices evolved during the pandemic and post-pandemic years.
    —The significant role of nature and prayer in maintaining hope.
    —The connection between spirituality and mental well-being.

    Our comprehensive survey of over 3,600 Americans offers a unique window into how spirituality has not only adapted but also thrived amidst adversity.

    Findings That Matter:
    This study is more than just numbers — it’s about real people and real experiences. It’s a journey into the sacred heart of what keeps us grounded in times of crisis. Discover trends in spiritual beliefs and practices in a pre-pandemic and post-pandemic comparison — some may surprise you. Understand the diverse ways in which spirituality provides resilience.
    Gain a deeper appreciation for the varied spiritual experiences in this nation.

    Source: Fetzer Institute

    Source link

  • Do You Have the Flu, RSV, COVID, or the Common Cold?

    Do You Have the Flu, RSV, COVID, or the Common Cold?

    Winter is almost here, and with it may come runny noses, coughing, and congestion. But how do you know if you just have a common cold, or if you have one or more of the three respiratory viruses that make up the “tripledemic” – RSV (respiratory syncytial virus), COVID-19, and influenza?

    Source link

  • A new COVID variant, HV.1, is now dominant. These are its most common symptoms

    A new COVID variant, HV.1, is now dominant. These are its most common symptoms

    As the United States enters respiratory virus season and health officials roll out updated COVID-19 vaccines, a new COVID variant HV.1 has emerged and is currently sweeping the country.

    The new omicron subvariant has rapidly overtaken other strains, including EG.5 aka Eris, to become the dominant variant in the U.S. As of late October, HV.1 is responsible for more than a quarter of all COVID-19 cases, and health officials are monitoring the new variant amid concerns of a winter COVID-19 surge.

    HV.1 accounted for an estimated 25.2% of new COVID-19 cases during the two-week period ending Oct. 28, according to the latest data from the U.S. Centers for Disease Control and Prevention.

    After HV.1, the next most common variant in the U.S. was EG.5, which made up 22% of cases, followed by FL.1.5.1 or “Fornax,” and XBB.1.16 or “Arcturus.” (Globally, EG.5 is still the dominant strain, according to the World Health Organization.)

    All of the most prevalent COVID-19 strains in the U.S. are offshoots of omicron, which first emerged in November 2021.

    Although COVID-19 cases and hospitalizations have been trending downward after a late summer surge, HV.1 is continuing to pick up speed around the country.

    Cases are expected to increase again this winter as was the case the past three years, Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, tells TODAY.com.

    As HV.1 spreads, many are curious if the new subvariant is more contagious or severe, whether it could cause different symptoms, and if the new COVID-19 vaccines will provide protection. Here’s what we know about HV.1 so far.

    What is HV.1, the new COVID variant?

    HV.1 is part of the omicron family. “You can almost think of HV.1 as a grandchild of omicron,” says Schaffner. HV.1 is a sublineage of omicron XBB.1.9.2 and a direct descendent of EG.5, according to the CDC’s SARS-CoV-2 lineage tree.

    “The COVID family of viruses likes to mutate. We’ve all learned that by now,” says Schaffner. While HV.1 is mutated, it’s still very close to the existing omicron subvariants, Schaffner explains.

    For the most part, scientists are not concerned about new variants like HV.1, which look very similar to strains we’ve already seen before, NBC News reported.

    However, there are a few highly mutated strains which have set off alarm bells. These include BA.2.86 or Pirola, which has an extra 36 mutations that differentiate it from XBB.1.5., and a newer variant called JN.1, which has one more mutation than Pirola.

    Fortunately, neither BA.2.86 nor JN.1 are common in the U.S. right now, according to the CDC — JN.1 is so rare that it makes up fewer than 0.1% of SARS-CoV-2 cases.

    As for HV.1, it rapidly gained steam after it was first detected this past summer. In late July, HV.1 accounted for just 0.5% of COVID-19 cases in the U.S., CDC data show. By Sept. 30, HV.1 made up 12.5% of cases, and by November, it was the dominant strain.

    Is HV.1 more transmissible?

    “One of the characteristics of this entire omicron family is that they are highly transmissible,” says Schaffner. Sometimes, mutations can enable a new variant to spread more effectively or quickly, per the CDC.

    Right now, it appears that HV.1 could be slightly better at spreading from person to person than previous strains, NBC News reported. The increased transmissibility of HV.1 likely explains how it became dominant so quickly in the U.S., Schaffner notes.

    It appears that HV.1 could also be slightly better at escaping prior immunity to COVID-19, but not enough to cause alarm, Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, told NBC News.

    Although it is more transmissible, HV.1 does not appear to produce more severe disease or lead to more hospitalizations, Schaffer says.

    What are HV.1 symptoms?

    The symptoms caused by infection with HV.1 are similar to those caused by recent variants, says Schaffner, which include:

    • Sore throat

    • Congestion or stuffiness

    • Runny nose

    • Cough

    • Fatigue

    • Headache

    • Muscle aches

    • Fever or chills

    “Congestion, sore throat and dry cough seem to be the three most prominent symptoms right now,” says Schaffner.

    Increasingly, doctors report that COVID-19 symptoms appear to follow a pattern of being concentrated in the upper respiratory tract, starting with a sore throat and followed by congestion or a runny nose, NBC news reported.

    Coughing isn’t typically a primary symptom, but it can persist. “The virus seems to produce a kind of a chronic bronchitis, so that you can have a cough syndrome that lasts beyond the period where you’ve recovered from other symptoms,” says Schaffner.

    Another trend is that COVID-19 seems to be causing milder infections, likely because people have some prior immunity. “By milder, we mean it doesn’t require hospitalization even though you can feel quite miserable for several days,” says Schaffner.

    Do COVID-19 tests detect HV.1?

    All COVID-19 tests — including PCR tests performed by a health care provider and rapid at-home antigen tests — will detect HV.1, says Schaffner.

    Testing is a crucial tool to protect yourself and others from COVID-19. The symptoms of HV.1 and other COVID-19 variants can look very similar to other viruses, including respiratory syncytial virus (RSV), influenza and rhinovirus, which usually causes the common cold.

    “The only way to distinguish (COVID-19) from RSV and flu, both of which are now gaining steam, is by testing,” says Schaffner.

    Experts encourage anyone who has symptoms to get tested, especially those in high-risk groups — people over the age of 65, who are immunocompromised or who have underlying health conditions.

    “We have treatments that can prevent more serious disease,” says Schaffner, but early detection is key. COVID-19 antivirals such as Paxlovid are effective against HV.1 and other variants, but they work best when within five days of symptom onset, TODAY.com previously reported.

    Testing has significantly diminished in the U.S. in the last year, which is concerning, says Schaffner.

    When the U.S. federal public health emergency for COVID-19 ended in May, so did the guarantee of free testing for many people.

    However, every American can still get COVID-19 tests for free or low-cost right now. One way is to order four free at-home COVID-19 tests from the government, which will be delivered by mail via the U.S. Postal Service. To order your free tests, go to COVIDTests.gov.

    In addition, all health insurance plans are required to reimburse eight at-home COVID-19 tests per month, according to the Centers for Medicare & Medicaid Services. State Medicaid programs are also required to cover at-home tests, and Medicare beneficiaries and uninsured individuals can access free tests provided by Health & Human Services at thousands of community health centers, clinics and pharmacies.

    If you still have a stockpile of tests sitting around, remember to check the expiration date and whether it’s been extended by the U.S. Food and Drug Administration.

    Does the new COVID-19 vaccine protect against HV.1?

    The updated COVID-19 vaccine is recommended by the CDC for everyone ages 6 months and older. It is now widely available at pharmacies, doctor’s offices and other locations around the U.S., says Schaffner.

    The new boosters have been reformulated to target omicron XBB.1.5, which was the dominant COVID variant for most of 2023. While XBB.1.5 has since been overtaken by HV.1, Eris, Fornax and Arcturus, it is still closely related to these newer strains.

    The updated vaccines seem to be well-matched to the variants currently circulating and making people sick, Andrew Pekosz, Ph.D., virologist at Johns Hopkins University, previously told TODAY.com.

    “Laboratory studies indicate that the updated booster will protect against serious disease caused by HV.1,” says Schaffner. Vaccination also significantly lowers the risk of becoming hospitalized or dying, per the CDC.

    However, only 23 million Americans or 4.5% of the population had received the updated shots by Oct. 27, Reuters reported.

    The first phase of the new booster rollout hit several speed bumps, including supply delays, high demand, cancelled appointments and insurance obstacles. Some parents have been unable to get their kids vaccinated as some pharmacies and pediatrician’s offices have struggled to secure enough child-size doses.

    Although many of these initial issues have been resolved, says Schaffner, uptake is still slow. “We’ve underutilized this updated vaccine, and we anticipate that COVID will once again increase even more during the winter season,” says Schaffner.

    It’s not too late to take advantage of the new booster, Schaffner adds, and people should get the shot as soon as they can.

    The FDA has authorized three vaccine options for 2023-2024: one mRNA shot each from Moderna and Pfizer, and a protein-based non-mRNA shot from Novavax.

    Insurance plans should cover the updated booster, says Schaffner, and those without insurance should still be able to get the shot for free, according to the CDC.

    “We’re in a good place because for a considerable time now, we have not had a new variant that causes more severe disease or evades the protection of currently available vaccines,” says Schaffner.

    How to protect yourself from HV.1

    As the winter and holiday season approaches, it’s important to take steps to protect yourself from COVID-19 and prevent transmission to others, especially the most vulnerable. These include:

    • Staying up to date with COVID-19 vaccines

    • Getting tested if you have symptoms

    • Isolating if you are testing positive for COVID-19

    • Avoiding contact with sick people

    • Improving ventilation or gathering outdoors

    • Washing your hands with soap and water frequently

    • Wearing a mask in crowded, indoor spaces

    This article was originally published on TODAY.com

    Source link

  • The real Covid jab scandal is finally emerging

    The real Covid jab scandal is finally emerging

    I am not an anti-vaxxer but… On 29 April 2021, Lisa Shaw, a clever, sensible, creative, mischievous, award-winning presenter at BBC Radio Newcastle, had her first Covid vaccination. Like millions of us, Lisa was delighted and relieved to get her jab. Not only did the 44-year-old mother of one feel she was doing her bit to keep her community safe (Lisa had been astonished a few weeks earlier when a girlfriend had said she wasn’t getting jabbed), she was excited “to give her mam a hug”.

    A few days later, Lisa developed a headache and stabbing pains behind her eyes which wouldn’t go away. By May 16, she was taken by ambulance to University Hospital of North Durham. Tests revealed blood clots in Lisa’s brain and she was moved to a specialist neurology unit in Newcastle. By now, she had difficulty speaking. Scans showed she had suffered a haemorrhage in the brain and part of her skull was removed to try and relieve the pressure. Her husband Gareth Eve remained by his wife’s bedside, but Lisa told him to go home because she was worried about Zachary, their six-year-old. One final kiss. The last time Gareth heard her voice. Lisa Shaw died on May 21 from complications arising from the AstraZeneca Covid vaccination.

    The coroner said: “Ms Shaw was previously fit and well” but it was “clearly established” that her death was due to a very rare “vaccine-induced thrombotic thrombocytopenia (VITT)”, a new condition which leads to swelling and bleeding of the brain.

    Strenuous efforts had been made to put the public’s mind at rest when the jab was approved. The Oxford/AstraZeneca vaccine was “a great British success story”, according to the then health secretary Matt Hancock; self-obsessed numpty that he is, Hancock was particularly chuffed the jab had been invented by someone who went to his Oxford college. “It is truly fantastic news – and a triumph for British science – that the @UniofOxford/@AstraZeneca vaccine has been approved for use,” tweeted a triumphant prime minister Boris Johnson.

    At a dark time, the AZ jab brought a blazing ray of hope with the added patriotic, Brexit bonus that the UK was able to steal a march on our European neighbours. After Lisa Shaw died, we were told that the clots are “considered extremely rare,” there had only been 417 reported cases and 72 deaths after 24.8 million first doses and 23.9 million second doses of the AstraZeneca vaccine in the UK. It also saved a great many lives. But expressing reservations about possible side-effects was seen as party-pooping. It meant you ran the risk of being labelled as that most reviled and irresponsible being, an “anti-vaxxer”.

    “I had lost my wife and my son had lost his mam, but for an awfully long time people like us weren’t able to tell our story because we were put in the box of crackpots and conspiracy theorists,” Gareth Eve told me yesterday. After Lisa died, Gareth says he had phone conversations with several leading broadcasters. “They would express sympathy, but then they were very nervous, they’d say they have to be very careful, you know, how they report the story without breaching broadcasting guidelines by implying there was any problem with the jab.”

    One beautiful vibrant woman, “loved by everyone whose lives she touched”, was gone. (“I wish it had been me instead of her,” Gareth says, “I do my best as a single dad with Zach, but I’m never going to be Lisa, she was so tactile and loving.”) The fact Lisa Shaw had died after receiving the AZ jab was nothing to worry about, though, in the grand scheme of things, was it?

    Well, yes, actually it was. The public – and in particular fit younger people like Lisa – have every right to feel aggrieved.

    As this newspaper reported yesterday, the Oxford-AstraZeneca Covid-19 vaccine has been branded “defective” in a multi-million pound landmark legal action which will suggest that claims over its efficacy were “vastly overstated”.  The pharmaceutical giant is being sued in a test case by Jamie Scott, a father-of-two who suffered a significant permanent brain injury, and by the widower and two young children of 35-year-old Alpa Tailor. Both damages claims relate to VITT, the condition that killed Lisa Shaw. AstraZeneca says that the vaccine “has continuously been shown to have an acceptable safety profile” and that “regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side-effects.”

    In the months after her death, Gareth, who was “dealing with grief while you’re trying to parent” didn’t have the emotional energy for a legal battle. “I was in the Coroner’s Court in Newcastle when the coroner said there is no doubt Lisa died because of the AstraZeneca jab and the pathologist said the same and the doctor told Lisa while she was still conscious that the Covid jab had done this to her. It’s like they don’t want there to be any written record that they admitted guilt.”

    I must admit there is a strong sense of, “There but for the grace of God go I” when I hear Gareth talking about his wife. I also had the AstraZeneca jab (twice) because, like Lisa, I wanted to reassure my elderly mother and hug her after over a year apart.

    We were all given the impression that the jab could prevent both infection and transmission (why else would they make it mandatory for care home workers?) It sounded brilliant. But the legal claim states, “the absolute risk reduction concerning Covid-19 prevention was only 1.2 per cent”.

    “Lisa thought getting the jab was the right thing to do as everybody did,” Gareth recalls, “The Government kept saying it was safe and effective. We didn’t know there were other countries that were withdrawing the AstraZeneca.”

    Ah, yes, “safe and effective”. How many times did we hear Cabinet ministers intone that reassuring mantra? Yet, use of the word “safe” by any pharmaceutical company advertising a product had been banned for years for exactly that reason – it is misleadingly reassuring. (The Government seems to think the rules didn’t prevent it saying “safe and effective” because it wasn’t advertising a specific product: a Mandy Rice Davis if ever I heard one.)

    Where, you might well ask, was the MHRA (Medicines and Healthcare products Regulatory Agency)? Ben Kingsley, a lawyer and co-author of a brilliant and damning new book, The Accountability Deficit, says: “For good reason, the MHRA’s rules did not allow AstraZeneca to promote its vaccine as ‘safe’. Yet, astonishingly, while a raft of other countries were pulling the AZ jab for safety reasons the British regulator stood aside with tragic consequences for Lisa and her family while ministers and the NHS continued to insist that it remained unequivocally safe and effective.”

    It is almost too painful to consider that, 15 days before Lisa Shaw went eagerly to get her Covid jab so she could “hug my mam”, Denmark stopped the use of AstraZeneca in its vaccination rollout after reports of rare but serious cases of blood clots. Finland also announced that it would continue to limit the AstraZeneca vaccine to people aged 65 and over following similar health concerns. Was the MHRA unaware of growing international doubts (AZ was never licensed in the US) or was it, perhaps, rather reluctant to tarnish a great British success story?

    In ethical terms, for a vaccine to be rolled out to people who are not at significant risk from Covid, it would need to be shown to be very safe indeed for those groups. I also clearly remember the head of the Government’s Vaccine Taskforce, Kate Bingham, saying that vaccinating everyone in the country was “not going to happen”. “It’s an adult-only vaccine, for people over 50, focusing on health workers and care home workers and the vulnerable,” she said. Vaccination policy would be aimed at those “most at risk”. She noted that vaccinating healthy people, who are much less likely to have severe outcomes from Covid-19, “could cause them some freak harm”, potentially tipping the scales in terms of the risk-benefit analysis.

    With a heavy heart I’m going to say what should have been said a long time ago. Unlike those who were actually vulnerable to Covid, Lisa Shaw did not need a Covid vaccine; any minuscule benefit to her was outweighed by the small risk. Neither did I (I’d had the virus in January 2020 as plentiful antibodies later attested and enjoyed good immunity). Millions of healthy people queued up for a jab they didn’t require which protected against serious disease in the elderly and vulnerable, but was not necessary for most of the rest of us.

    How this country moved from a policy of only vaccinating those who would benefit to running the risk of inflicting “some freak harm” on people like Lisa Shaw may yet turn out to be one of the great scandals of the age.

    “I put her on a pedestal,” Gareth Eve says of his late wife, “Lisa was only 5ft 2 and I’m 6 foot, but I put her on a pedestal. She was that wonderful. When she died, because of the way that she died after the jab, it was ‘a dirty secret’, you weren’t supposed to talk about. With AstraZeneca, these companies are run by human beings, you would have thought they were run by human beings, Allison, but they don’t want to talk to the people like me…Zachary doesn’t have his mam because the authorities didn’t give us the full picture about the risks.”

    I am not an anti-vaxxer but…. Let’s stop saying that, shall we? There’s no shame in being against giving a vaccine to groups who didn’t need it, and which caused people to be dead who should be alive and taking their eight-year-old son to school.

    Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month, then enjoy 1 year for just $9 with our US-exclusive offer.

    Source link

  • US adds another option for fall COVID vaccination with updated Novavax shots | Long Island Business News

    US adds another option for fall COVID vaccination with updated Novavax shots | Long Island Business News

    U.S. regulators on Tuesday authorized another option for fall COVID-19 vaccination, updated shots made by Novavax.

    Updated vaccines from Pfizer and Moderna began rolling out last month, intended for adults and children as young as age 6 months. Now the Food and Drug Administration has added another choice –- reformulated Novavax shots open to anyone age 12 and older.

    The Centers for Disease Control and Prevention already has urged most Americans to get a fall COVID-19 vaccination, shots tweaked to protect against a newer coronavirus strain. Novavax said shots will be available “in the coming days.”

    Protection against COVID-19, whether from vaccination or from an earlier infection, wanes over time. There’s already been a late-summer increase in infections, and health officials hope enough people get the new shots to blunt a winter wave.

    Novavax makes a protein-based vaccine mixed with an immune-boosting chemical, a different technology than the so-called mRNA vaccines made by Pfizer and Moderna.

    While Pfizer and Moderna have shipped millions of doses, the fall rollout so far has been messy since, for the first time, the government isn’t buying and distributing the COVID-19 shots. Ordering confusion from drugstores and doctors’ offices, distribution delays and even bungled paperwork by insurance companies snarled early appointments.

    The updated vaccine versions are supposed to be free through private insurance or Medicare, and the CDC has a program to temporarily provide free shots to the uninsured or underinsured.

    The Associated Press

    Source link

  • Federal student loan payments are starting again. Here’s what you need to know | Long Island Business News

    Federal student loan payments are starting again. Here’s what you need to know | Long Island Business News

    Federal student loan borrowers will need to start making payments again this month after a three-year-plus pause due to the pandemic.

    You should expect a bill that lays out how much you have to pay each month at least 21 days before your due date. It’s likely that most borrowers have received their bill already but if you have not, visit your loan servicer account. Interest started accruing again in September.

    If you have student loans and haven’t made a payment in the last three years, don’t panic. Here’s what experts recommend:

    WHERE DO I START?

    The first step is to log in to your StudentAid.gov account and check who your loan servicer is. Many loan servicers changed during the pandemic, so you might have a different one than you did back in March 2020, said Amy Czulada, outreach and advocacy manager at the Student Borrower Protection Center.

    Once you know your loan servicer, you’ll log into your account with them to access your student loan balance, monthly payment amount and interest rate. Czulada also recommended that you look at which type of student loan you have, so you know which income-driven repayment plans you might qualify for.

    Lastly, update your personal information in your account with your loan servicer to make sure you receive all important correspondence.

    HOW DO I KNOW WHAT MY PAYMENTS WILL BE?

    Borrowers can find out what their monthly student loan payment will be on their account with their loan servicer. If you don’t know who your servicer is, you can find it by logging in your studentaid.gov account.

    WHAT IF MY PAYMENTS ARE TOO HIGH?

    If you think you’ll have a hard time making payments once they resume, you have several options.

    This summer, President Joe Biden announced a 12-month grace period to help borrowers who struggle after payments restart. You can and should make payments during the first 12 months after payments resume, but if you don’t, you won’t be at risk of default and it won’t hurt your credit score. Interest will accrue whether you make payments or not.

    Betsy Mayotte, president of The Institute of Student Loan Advisors, recommends that you research if you qualify for an income-driven repayment plan. Borrowers can use the loan-simulator tool at StudentAid.gov or the one on TISLA’s website to find a payment plan that best fits their needs. The calculators tell you what your monthly payment would be under each available plan, as well as your long-term costs.

    WHAT’S AN INCOME-DRIVEN REPAYMENT PLAN?

    An income-driven repayment plan sets your monthly student loan payment at an amount that is intended to be affordable based on your income and family size. It takes into account different expenses in your budget, and most federal student loans are eligible for at least one of these types of plans.

    Generally, your payment amount under an income-driven repayment plan is a percentage of your discretionary income. If your income is low enough, your payment could be $0 per month.

    Last year, the Biden administration announced a new income-driven repayment plan. The SAVE plan offers some of the most lenient terms ever. On this plan, interest won’t pile up as long as borrowers make regular payments.

    It’s still possible that the SAVE plan could face legal challenges similar to the one that led the Supreme Court to strike down Biden’s proposal for mass student loan cancellation.

    ARE THERE ANY OTHER PROGRAMS THAT CAN HELP WITH STUDENT LOAN DEBT?

    If you’ve worked for a government agency or a nonprofit, the Public Service Loan Forgiveness program offers cancellation after 10 years of regular payments, and some income-driven repayment plans cancel the remainder of a borrower’s debt after 20 to 25 years.

    Borrowers should make sure they’re signed up for the best possible income-driven repayment plan to qualify for these programs.

    Borrowers who have been defrauded by for-profit colleges may also apply for borrower defense and receive relief.

    If you’d like to repay your federal student loans under an income-driven plan, the first step is to fill out an application through the Federal Student Aid website.

    HOW CAN I REDUCE COSTS WHEN PAYING OFF MY STUDENT LOANS?

    If you sign up for automatic payments, the servicer takes a quarter of a percent off your interest rate.

    HOW DO I ENROLL IN AUTOMATIC PAYMENTS?

    You can enroll in automatic payments through your loan servicer’s account. Borrowers who were enrolled in automatic payments prior to the payment pause need to re-enroll again, said Czulada.

    WHAT ELSE SHOULD I KNOW?

    Czulada recommends staying vigilant about scams. You should never have to pay to get help with your loans or to apply for any programs.

    “The Department of Education will never call you on the phone. So, if you’re getting a phone call that says ‘Hey, pay $100 now and you’ll get your debt canceled,’ that’s a red flag that it’s a scammer,” said Czulada.

    To protect yourself from scams, the Department of Education recommends that you know their official email addresses, check for typos in advertisement and never share your log-in information.

    The Associated Press

    Source link

  • 5 things to know about the new COVID-19 vaccine

    5 things to know about the new COVID-19 vaccine

    It may be time to get your COVID-19 vaccine again.

    There’s a new booster that’s coming out to guard against the virus. The Centers for Disease Control and Prevention said Tuesday that it was recommending the vaccine, which is being produced in versions by Moderna
    MRNA,
    +3.18%

    and Pfizer
    PFE,
    -0.20%

    -BioNTech
    BNTX,
    -2.06%
    ,
    for people 6 months of age and older.

    Here are answers to some common questions about the shot — and what you may need to know before you receive it.

    Why are we seeing another booster?

    Boosters are all about maintaining protection against the virus as new COVID-19 variants emerge. The CDC said: “The updated vaccines should work well against currently circulating variants of COVID-19, including BA.2.86, and continue to be the best way to protect yourself against severe disease.” The CDC also noted that “protection from COVID-19 vaccines and infection decline over time. An updated COVID-19 vaccine provides enhanced protection against the variants currently responsible for most hospitalizations in the United States.”

    So, everyone who is 6 months or older should receive it?

    That’s the CDC’s recommendation, but not everyone sees this booster as a firm requirement, depending on various medical and other factors.

    Dr. Paul A. Offit, a pediatrician with the Children’s Hospital of Philadelphia who specializes in infectious diseases, told MarketWatch that the new vaccine is a must for some who are at higher risk for developing serious illness, such as people who are over 75, people who have certain health problems (including diabetes, obesity or chronic lung or heart disease) and people who are immune compromised.

    And what about the others? Offit said it can be a case of “low risk, low reward.” Meaning there’s little harm in getting the booster and it may buy “a few months protection against mild disease,” Offit said. But he stops short of saying the booster is an absolute necessity for such people.

    Still, CDC director Dr. Mandy K. Cohen counters such an argument. In a column for the New York Times, Cohen noted that all the members of her family, including her 9- and 11-year-old daughters, would be getting the booster. “Some viruses…change over time. This coronavirus is one of them. It finds ways to evade our immune systems by constantly evolving. That’s why our vaccines need to be updated to match the changed virus,” Cohen explained.

    What if you recently had COVID? Or have just gotten the previous COVID booster?

    Offit said you should wait at least two months — and possibly as long as four months — before receiving the new vaccine.

    The CDC said, “You should get a COVID-19 vaccine even if you already had COVID-19,” adding “you may consider delaying your next vaccine by 3 months from when your [COVID] symptoms started or, if you had no symptoms, when you received a positive test.”

    When and where can you get the new booster?

    The CDC said the vaccine “will be available by the end of this week at most places you would normally go to get your vaccines.”

    How much will it cost?

    The new shots are expected to have list prices of $110 to $130, but the CDC said, “Most Americans can still get a COVID-19 vaccine for free.” That is, most health-insurance plans will cover the cost.

    As for those without insurance, the CDC said there are still plenty of free options, including programs run by local health centers and health departments as well as pharmacies participating in the CDC’s Bridge Access Program. For more information about where to get the booster, go to Vaccines.gov.

    Source link

  • CDC recommends updated COVID shots for people 6 months of age and older

    CDC recommends updated COVID shots for people 6 months of age and older

    The Centers for Disease Control and Prevention on Tuesday recommended updated COVID-19 vaccines for people 6 months of age and older.

    Director Mandy Cohen late Tuesday backed the findings of CDC advisers, who voted 13-to-1 for approval earlier in the day. The updated vaccines from Moderna Inc.
    MRNA,
    -0.53%

    and Pfizer Inc.
    PFE,
    +0.62%

    -BioNTech
    BNTX,
    -1.97%

    should become available later this week.

    “We have more tools than ever to prevent the worst outcomes from COVID-19,” Cohen said in a statement. “CDC is now recommending updated COVID-19 vaccination for everyone 6 months and older to better protect you and your loved ones.”

    The move comes just one day after the U.S. Food and Drug Administration approved the updated shots from Moderna and Pfizer. The FDA approved single-dose vaccines for people 12 and older and authorized emergency use of new shots for children as young as 6 months.

    The CDC recommendations Tuesday include some key changes from the recommendations that previously applied to the bivalent COVID vaccines. People age 65 and older were recommended to get a second bivalent dose, for example, but the CDC is not currently recommending two doses of the new shot for older adults. The CDC said it will monitor epidemiology and vaccine effectiveness to determine if additional doses are needed.

    The recommendations come as the vaccines are transitioning from federal procurement and distribution to the commercial market. The new shots are expected to have list prices of $110 to $130 per dose. But the Affordable Care Act requires insurers to cover most vaccines recommended by the CDC advisory committee at no cost to plan enrollees, and people with Medicare and Medicaid also have no-cost access to the vaccines. 

    The CDC meeting Tuesday addressed some concerns about the accessibility and cost of the vaccines for people without health-insurance coverage. The CDC’s new Bridge Access program will provide free shots to uninsured people within days at retail pharmacies as well as local health centers, the CDC said. The agency had previously said that the free shots might not arrive in retail pharmacies until mid-October. The federal government’s vaccines.gov website will be updated later this week to list Bridge Access program sites, the CDC said.

    Roughly 25 million to 30 million U.S. adults do not have health insurance. About 85% of people without coverage live within 5 miles of a Bridge Access program site, according to CDC data.

    Under the Bridge Access program, CVS Health Corp.
    CVS,
    +2.57%

    will administer doses in stores and Minute Clinics, the CDC said, and Walgreens Boots Alliance Inc.
    WBA,
    +1.35%

    will offer doses in stores and at off-site events that target areas of low access and uptake. Healthcare-services company eTrueNorth is also working with the program to reach lower-access areas without other coverage under the program, the CDC said.

    Source link

  • The post-COVID live music scene: There’s some good news and some bad news – National | Globalnews.ca

    The post-COVID live music scene: There’s some good news and some bad news – National | Globalnews.ca

    For almost two years, COVID-19 saw to it that there was no live music. Tours stopped, roadies lost their gigs, venues suffered, and support staff were laid off. But once COVID restrictions were lifted, the industry came back to life, albeit with a non-insignificant degree of difficulty.

    For example, Sum 41’s Deryck Whibley told me that when they returned to the road, they had to do it old-school in a van because no tour buses were available. Most had been parked for nearly two years and weren’t roadworthy yet. Supply and demand jacked the prices of any rental agency that did have buses available and those were taken by acts who could afford it. Sum’s buses ended up going to Metallica.

    There were other problems. Many roadies who were thrown out of work left the industry and didn’t want to come back. Finding enough sound and light equipment to rent was hard. Many venues didn’t survive the lockdowns and had permanently shut their doors.

    Story continues below advertisement

    But this summer has seen a return to The Before Times. Concerts and festivals have been packed. And even as Taylor Swift and Beyonce are getting the most attention for hoovering up hundreds and hundreds of millions of dollars in box office revenue, other acts are doing well.

    On his current tour, Drake is playing in front of as many as 34,000 people a night and recently became the first rapper to earn over US$5 million for a single show. Ed Sheeran’s BC Place gig on Sept. 2 attracted 65,601 people, breaking a 2009 record held by U2 set during their 360 Tour. The Weeknd broke attendance records in London by bringing in over 160,000 people over two nights. A swing through Australia saw 120,000 join him for two nights in Brisbane, close to 250,000 over three nights in Sydney, and somewhere north of 150,000 for two shows in Melbourne.

    My home market, Toronto, has seen incredible demand over the summer with acts routinely backing 17,000 people into Live Nation’s Budweiser Stage. And woe to anyone trying to get around downtown on a night there’s a concert at Scotiabank Arena, especially when the Blue Jays have a home stand at Rogers Centre.

    Live Nation and AEG, the world’s largest concert promoters, are seeing record revenues. One estimate says that live music revenue in Canada will hit somewhere around $1.3 billion with a projected annual growth rate of over three per cent. The average spend by a Canadian concertgoer is approaching $200.

    Story continues below advertisement

    So all’s good, right? Mostly, but …

    Just like every other sector of the economy and society, the live music industry is dealing with rising costs, higher insurance premiums, higher interest rates for financing tours, servicing debts left over from COVID-19, airfare and accommodation needs, and other financial pressures. There are stories about porta-potties being in such high demand that some festivals have been underserved. And there’s plenty of opportunistic gouging, too. Someone sent me a picture of an ordinary service parking lot in Seattle that was charging $120 a spot for a Taylor Swift show.

    Running a small-to-mid-sized venue is increasingly difficult because there’s a limit to how much operators can scale things. It’s far easier for Live Nation to juggle rising costs than it is for a 250-capacity bar that wants to feature live acts. These challenges are reflected not only in higher ticket prices but increases on what we have to pay for parking, concessions, and alcohol at shows.

    Which brings me to Gen Z. These young fans born between 1997 and 2012 are the lifeblood of so many live scenes. They seem especially sensitive to buying booze at gigs. Reports are that they’re drinking less, putting a big kink into an important revenue stream. Young fans are either pre-drinking before heading out or opting for a couple of edibles before going to the show. Many are pursuing a more straight-edge lifestyle, eschewing alcohol and drugs in pursuit of better mental health. Since smaller venues greatly depend largely on bar sales for survival, there’s cause for worry. And how can you fault Gen Z for imbibing less of the demon alcohol?

    Story continues below advertisement

    Fewer sales at the bar have created a new problem: merch cuts.

    An important revenue stream for artists is the sale of T-shirts and other souvenir ephemera at shows. Because these sales take up floor space, venues demand a cut of sales. To compensate for higher costs and lower alcohol sales, venues are demanding that they get more of a taste. It’s now not uncommon for a road manager to fork over 15 to 25 per cent of gross soft good sales (T-shirts and the like) along with additional vig on things like CDs and vinyl. These rates are often negotiable, but chances are the artist will end up paying something to the venue.

    Jeff Rosenstock, an American singer who’s been on the road for much of the summer, knows this all too well. He’s been documenting how much he’s had to fork over for merch cuts.

    Story continues below advertisement

     

    It’s really hard to take sides because both the small-to-medium-sized artist and the small-to-medium-sized venue are struggling with inflation, increased rents, a jump in taxes, and higher labour costs. Bigger performers also have to pay these fees but it’s certainly easier for a Taylor Swift to roll with the changes than it is for a punk band travelling from show to show in a 1977 Ford Econoline van and existing on leftover hotdogs scavenged from 7-11.

    There are other issues afoot. Dec. 31 is the deadline for repaying Canadian Emergency Business Account (CEBA) loans. Many venues across Canada were depending on that hand-up to survive through 2020 and 2021. The Canadian Live Music Association is worried that some of its members won’t be pay back those loans in time. If that happens, then what? Meanwhile, governments are also making noises about cutting back on the amount of money they get to the arts sector. That will inevitably impact the live music industry.

    High prices are here to stay. What lies ahead? Let’s examine that.

    Fans will have to make a choice between saving up their money to see a big act or using that same cash to see multiple smaller shows. Music residencies are also becoming more popular. Instead of artists travelling the world to reach their fans, more are opting to set up in a given city and have fans come to them. If, for example, you’re a Canadian fan of U2, your only current option to see them is to pay big American dollars for tickets to their residency at the MSG Sphere in Las Vegas. Plus fork out additional cash for airfare, hotel, and food, of course. Other acts are willing to play in venues like casinos. At least two major Ontario casinos opened new performance spaces this year, a trend that we’re seeing across the continent. Again, this puts the travel burden on the fan.

    Story continues below advertisement

    Back on the artist side, there’s the growing lure of playing corporate gigs. This has no bearing on the average concert fan and is generally restricted to well-off acts who are happy to take a couple of million dollars from some tech bro to play at a company retreat. But such paydays sometimes create a bad smell if word leaks out to the fanbase.

    So where do we go from here? How far can acts and promoters push us? Inflation and interest rates are prompting everyone to look at their discretionary spending. Entertainment is usually one of the first things that gets cut.

    Again, the big acts, the big venues, and the big promoters will probably end up doing just fine. But what about the little guy? I guess we’ll see.

    — with files from FYIMusicNews.ca

    Alan Cross

    Source link

  • New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    A new variant of the SARS-CoV-2 coronavirus has put epidemiologists around the world on alert, and the World Health Organization is asking countries to sustain early warning, surveillance and reporting systems as it works to evaluate the current COVID-19 risk level.

    The BA.2.86 variant, which was first detected in Israel, was designated a new variant under monitoring by the WHO on Aug. 17, after the agency received nine sequences from five countries — three in the WHO’s European Region, one in the African Region and one in the Region of the Americas.

    The variant has more than 30 mutations in the spike protein compared with the XBB variants that are currently dominant in the U.S. and around the world, namely XBB.1.16 and EG.5, which has been dubbed Eris, following the Greek-alphabet designation used for other variants.

    The WHO made EG.5 a variant of interest, or VOI, earlier this month, which is an upgrade from the designation of variant under monitoring, or VUM.

    But BA.2.86 is worrying experts because there is too little data to assess its potential impact.

    “It is crucial to sustain early warning, surveillance and reporting, variant
    tracking, early clinical care provision, administration of vaccine boosters to high-risk groups, improvements in ventilation, and regular communication,” the agency said in its latest weekly update.

    That update, which reviews the state of the virus for the 28-day period through Aug. 20, contains no data from the WHO’s Region of the Americas, as reports for the period were incomplete. That’s a worry that the WHO has consistently warned about as countries pull back on their monitoring of the illness as they seek to put the pandemic behind them.

    The WHO officially declared the emergency phase of the pandemic to be over on May 5 but emphasized that COVID remains a major threat. Many countries have dismantled much of their systems of oversight and greatly reduced testing and data measurement.

    See also: New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    The U.S. Centers for Disease Control and Prevention offered an update this week on BA.2.86 — which it said has been detected in Denmark, South Africa, Israel, the U.S. and the U.K. — and said the multiple locations are a sign of international transmission. The CDC acknowledged the surveillance challenge.

    “Notably, the amount of genomic sequencing of SARS-CoV-2 globally has declined substantially from previous years, meaning more variants may emerge and spread undetected for longer periods of time,” the U.S. agency said in its update.

    The CDC also noted a current increase in hospitalizations in the U.S., although it said that’s not likely driven by the BA.2.86 variant.

    “It is too soon to know whether this variant might cause more severe illness compared with previous variants,” said the CDC.

    Perhaps the bigger issue is whether the new variant has greater escape from existing immunity from vaccines and previous infections, compared with other recent variants.

    “One analysis of mutations suggests the difference may be as large as or greater than that between BA.2 and XBB.1.5, which circulated nearly a year apart,” the CDC said. “However, virus samples are not yet broadly available for more reliable laboratory testing of antibodies, and it is too soon to know the real-world impacts on immunity.”

    Americans gearing up for what’s expected to be an annual COVID vaccine booster this fall can be confident those vaccines will be designed to protect against all subvariants of XBB, including Eris, the agency said.

    The CDC said it’s likely that antibodies built up in the population through infection, vaccination or both will provide protection against BA.2.86. However, it said, “this is an area of ongoing scientific investigation.”

    Eric Topol, the chair of innovative medicine at Scripps Research in La Jolla, Calif., said the ability to neutralize the virus depends on the levels of neutralizing antibodies, and those are bound to be lower against BA.2.86 than earlier variants that people have been exposed to or immunized against.

    “Also to note, the burden of new mutations for BA.2.86 is not confined to the spike and is seen broadly across other components of the virus,” he wrote in commentary this week. “If BA.2.86 takes off, it will be a real test of how good our T-cell response can rev up to meet the challenge.”

    Meanwhile, the CDC’s weekly projections for where Eris and other variants are circulating continue to be hampered by a shortage of data. In early August, the CDC said it would unable to  publish its “Nowcast” projections because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch at the time.

    The agency had received data from just three U.S. regions. In its most recent weekly update for the week through Aug. 19, it also got data from just three regions.

    Separately, the CDC reported a 21.6% increase in U.S. hospitalizations for COVID in the week through Aug. 12. Deaths rose 21.4% in the week through Aug. 19.

    Source link

  • WHO names Eris a COVID variant of interest. Here’s what you need to know.

    WHO names Eris a COVID variant of interest. Here’s what you need to know.

    The World Health Organization has upgraded COVID-19 variant EG.5 to a variant of interest, or VOI, from a variant under monitoring, or VUM, as it continues to become more prevalent around the world.

    The variant — which has been nicknamed Eris by some media, following the Greek-alphabet designation used for other variants — has been found in 51 countries, with most sequences, 30.6%, stemming from China, said the WHO.

    Other countries that have submitted at least 100 sequences to a central database include the U.S., the Republic of Korea, Japan, Canada, Australia, Singapore, the United Kingdom, France, Portugal and Spain, the WHO said in a statement.

    Eris is a descendent lineage of XBB.1.9.2, which is an omicron subvariant. It was first detected on Feb. 17 and designated as a VUM on July 19.

    Its latest designation means it’s more prevalent than it was, has a growth advantage over earlier variants and merits closer monitoring and tracking.

    Here’s what you need to know about Eris.

    Eris is spreading around the world

    The strain is increasing in global prevalence, accounting for 17.4% of cases sequenced in the week through July 23, up from 7.6% four weeks earlier. The WHO has been tracking COVID data on a 28-day basis, largely because countries have cut back on testing and surveillance as they emerge from the pandemic, meaning the agency has far less data than it did during the pandemic.

    It’s already dominant in the U.S.

    Eris has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said last week it was unable to publish its “nowcast” projections, which it releases every two weeks, for where EG.5 and other variants are circulating for every region, because it did not have enough sequences to update the estimates.

    “Because nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch.

    “For some regions, we have limited numbers of sequences available and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast,” she said.

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and was more than any other variant.

    For more, see: New Eris COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    It’s no riskier than earlier variants

    The public-health risk is deemed to be low at the global level, lining up with the risk posed by XBB.1.16 and other currently circulating VOIs, according to the WHO statement. But it’s likely more infectious.

    “While EG.5 has shown increased prevalence, growth advantage, and immune escape properties, there have been no reported changes in disease severity to date,” said the WHO.

    That growth advantage and immune-escape properties mean Eris may cause a rise in case incidence over time and become dominant in some countries or even the world, according to the WHO.

    It has the same symptoms as other strains

    The Eris variant causes the same symptoms as seen with other strains of COVID, such as sore throat, runny nose, cough, congestion, fever, fatigue, body aches and a possible loss of taste or smell.

    The best defense against Eris is vaccination

    Like earlier strains of COVID, the best protection is to be vaccinated with any of the vaccines developed by Pfizer Inc.
    PFE,
    -0.03%

    and German partner BioNTech SE
    BNTX,
    -0.32%
    ,
    Moderna Inc.
    MRNA,
    -1.01%

    or Novavax Inc.
    NVAX,
    +9.83%

    The vaccines that will be made available in the fall will be designed to protect against all subvariants of XBB, including Eris.

    Source link

  • New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    A new variant of COVID-19 dubbed EG.5 has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said on Friday it was unable to publish its “Nowcast” projections for where EG.5 and other variants are circulating for every region, which it releases every two weeks, because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley said in a statement to CBS News.

    “For some regions, we have limited numbers of sequences available, and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast.”

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and more than any other variant.

    But the data are based on sequencing from just three regions; Region 2, comprising New Jersey, New York, Puerto Rico and the U.S. Virgin Islands; Region 4, comprising Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee; and Region 9, comprising Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and Republic of Palau.

    The next most common variants are XBB.1.16, accounting for 15.6% of cases, and XBB.2.3, accounting for 11.2% of cases.

    All are subvariants of XBB, which COVID vaccines in the fall will be designed to protect against.

    The symptoms of EG.5, which Twitter users have nicknamed “Eris,” are similar to early variants, and it’s not deemed to be more virulent than early variants. It may be more infectious, however, as has been the pattern with new strains. Symptoms include a cough, fever, chills, shortness of breath, fatigue and a loss of taste or smell.

    The World Health Organization said last week that EG.5 increased in prevalence globally to 11.6% in the week through July 30 from 62% four weeks earlier.

    The variant is for now a variant under monitoring, or VUM, for the agency, which is a less serious designation than a variant of interest, or VOI, according to its weekly epidemiological update.

    The WHO is monitoring two VOIs, XBB.1.5 and XBB.1.6.

    It is tracking seven VUMs and their descendent lineages, namely BA.2.75, CH.1.1, XBB, XBB.1.9.1, XBB.1.9.2, XBB.2.3 and EG.5.

    CDC data show that hospital admissions with COVID started to rise again in July after being flat or falling for several months. But the number of deaths continues to decline with 81.4% of the overall population in the U.S. having had at least one vaccine dose.

    Source link

  • COVID pandemic is officially over in the U.S., excess-deaths data show

    COVID pandemic is officially over in the U.S., excess-deaths data show

    The COVID-19 pandemic is definitively over, according to two recent reports focused on the same metric.

    That metric is excess deaths, a measure of the difference between the number of deaths that occurred through the pandemic years, beginning in March 2020, and the number that would be expected in a nonpandemic year, based on data from earlier years.

    At…

    Source link

  • With house prices this high, boomers may want to become renters

    With house prices this high, boomers may want to become renters

    If you’re a retiree and you’re trying to square the circle of rising costs, longer lifespans, more expensive medical care and turbulent markets, don’t be afraid to run the numbers on your biggest investment.

    That would be your home — if you own it.

    U.S. house prices are now so high that it is almost impossible for seniors not to ask themselves the obvious question: “Should we cash in, invest the money, and rent?”

    Right now the average U.S. house price is nearly $360,000. That’s about a third higher than just a few years ago, before the COVID-19 pandemic. The lockdowns, the panic, the stimulus checks and 2.5% mortgage rates have all passed into history. But the sky-high prices remain — for now.

    After several years of double-digit percentage increases, apartment-rent growth is falling for only the second time since the 2008 financial crisis. WSJ’s Will Parker joins host J.R. Whalen to discuss.

    At these levels, analysts at Realtor.com — which, like MarketWatch, is owned by News Corp.
    NWSA,
    +1.13%

    say that in 45 out of 50 major U.S. metropolitan areas it is cheaper to rent than it is to buy a starter home. The Atlanta Federal Reserve Bank says national housing affordability is abysmal — about where it was in 2006 and 2007, during the big housing bubble.

    There is a similar story for seniors. Federal data show that the average U.S. house price is now nearly 17 times the average annual Social Security benefit — an even higher ratio than it was in August 2008, just before Lehman Brothers collapsed. At that juncture, the average house price was 15 times higher.

    U.S. National Home Price Index vs. average rent of primary residence in U.S. city, according to the U.S. Bureau of Labor Statistics. Indexed: January 1987=100.


    S&P/Case-Shiller

    Our simple chart, above, compares average U.S. home prices with average U.S. rents, going back to 1987. (The chart simply shows the ratio, indexed to 100.) The bottom line? House prices are very high at the moment compared with rents — again, prices are about where they were in 2006-07.

    And the two must run in tandem over the long term, because the economic value of owning a house is not having to pay rent to live there.

    If there are times when, in general, it makes more financial sense for seniors to rent than to own, this has to be one of those.

    Seniors who own their own homes may think high interest rates on new mortgages don’t affect them. They most likely either already have a mortgage at a lower, older rate or they’ve paid off their home loan. But if you want to sell, you’ll almost certainly be selling to someone who needs a mortgage.

    If borrowing costs drive down real-estate prices, seniors who hold off on selling may miss out on gains they may never see again. After the last housing peak, in 2006, it took a full decade for prices to recover fully. Those who sold when the going was good had the chance to buy lifetime annuities at excellent rates or to invest in stocks and bonds that overall rose about 80% over the same period.

    As I mentioned recently, there is a broad basket of real-estate trusts on the stock market that are publicly traded landlords. You can sell your home and invest in thousands at a click of a mouse.

    But should you?

    Incidentally, there is also an exchange-traded fund that invests in residential REITs, Armada’s Residential REIT ETF
    HAUS,
    -0.53%
    ,
    though in addition to single-family homes and apartment-complex operators, about 25% of the fund is invested in companies involved in manufactured-home parks and senior-living facilities.

    For each person, the math will be different, and there are a number of questions you need to ask. Where do you want to live? How much would you get if you sold your house? How much would you pay in taxes? How much would it cost to rent the right place? Do you want to leave a property to your heirs? And what would be the costs of moving — both financial and emotional?

    The conventional wisdom is that you should own your home in retirement.

    “I would advise any and all retirees against renting if at all possible,” says Malcolm Ethridge, a financial planner at CIC Wealth in Rockville, Md. “You need your costs to be as fixed as possible during retirement, to match your income being fixed as well. If you choose to rent, you’re leaving it up to your landlord to determine whether and by how much your No. 1 expense will increase each year. And that makes it very tough to determine how much you are able to allocate toward everything else in your budget for the month.”

    A key point here, from federal data, is that nationwide rents have risen year after year, almost without a break, at least since the early 1980s. They even rose during the global financial crisis, with just one 12-month period where they fell — and then by only 0.1%.

    “My general advice for clients is that owning a home with no mortgage in retirement is the best scenario, as housing is typically the highest cost we pay monthly,” says Adam Wojtkowski, an adviser at Copper Beech Wealth Management in Mansfield, Mass. “It’s not always the case that it works out this way, but if you can enter retirement with no mortgage, it makes it a lot easier for everything to fall into place, so to speak, when it comes to retirement-income planning.”

    “Renting comes with a lot of risk,” says Brian Schmehil, a planner with the Mather Group in Chicago. “If you rent, you are subject to the whims of your landlord, and a high inflationary environment could put pressure on your finances as you get older.”

    But it’s not always that simple.

    “With housing costs as high as they are now though, renting may be a viable solution, at least for the moment,” says Wojtkowski. “We don’t know what the housing-market trends will be going forward, but if someone is waiting for a housing-market crash before they move, they could very likely be waiting for a long time. We just don’t know.”

    “Any decision comes with pros and cons,” says Schmehil. “Selling when your home values are historically high and renting allows you to capture the equity in your home, which is usually a retiree’s largest or second-largest financial asset. These extra funds allow you to spend more money on yourself in retirement without having to worry about doing a reverse mortgage or selling later in retirement, when it may be harder for you to do so.”

    Renting also allows you to be more flexible about where you live, for example nearer your children or grandchildren, he adds.

    And as any experienced property owner knows, renting also brings another benefit: You no longer have to do as much work around the house.

    “Renting is great in that you don’t need to maintain a residence,” says Ann Covington Alsina, a financial planner running her own firm in Annapolis, Md. “If the dishwasher breaks or the roof leaks, the landlord is responsible.”

    Wojtkowski agrees, noting that many people no longer want to spend time mowing the lawn or shoveling snow in retirement. “Ultimately, one of the things that I’ve seen most retirees most concerned with is eliminating the general upkeep [and] maintenance of homeownership in retirement,” he says.

    Several planners — including Covington Alsina and Wojtkowski — note that one alternative to selling and renting is simply downsizing. This can free up capital, especially when home prices are high, like now, without leaving you exposed to rising rents.

    Many baby boomers have been doing exactly that. 

    Meanwhile, I am reminded of my late friend Vincent Nobile, who — after a long and fruitful life owning homes and raising a family — found himself widowed and alone in his 80s. He rented a small cottage on a New England sound and said how glad he was that he never had to worry about maintaining the roof or the appliances, or fixing the plumbing or the heating, or any one of a thousand other irritations. Or paying property taxes — which go down even more rarely than rents.

    When the regular drives to Boston got too onerous, he moved into the city and rented there. And he was glad to do it. The money he had made was all in investments — a lot less hassle both for him and his heirs.

    I once asked him if he would prefer to own his own home. He shook his head and laughed.

    Source link